Cholestagel

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
25-05-2021

Ingredient activ:

colesevelam (as hydrochloride)

Disponibil de la:

CHEPLAPHARM Arzneimittel GmbH

Codul ATC:

C10AC04

INN (nume internaţional):

colesevelam

Grupul Terapeutică:

Lipid modifying agents

Zonă Terapeutică:

Hypercholesterolemia

Indicații terapeutice:

Cholestagel co-administered with a 3-hydroxy-3-methyl-glutaryl-coenzyme-A (HMG-CoA)-reductase inhibitor (statin) is indicated as adjunctive therapy to diet to provide an additive reduction in low-density-lipoprotein-cholesterol (LDL-C) levels in adult patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone.Cholestagel as monotherapy is indicated as adjunctive therapy to diet for reduction of elevated total cholesterol and LDL-C in adult patients with primary hypercholesterolaemia, in whom a statin is considered inappropriate or is not well tolerated.Cholestagel can also be used in combination with ezetimibe, with or without a statin, in adult patients with primary hypercholesterolaemia, including patients with familial hypercholesterolaemia (see section 5.1).

Rezumat produs:

Revision: 23

Statutul autorizaţiei:

Authorised

Data de autorizare:

2004-03-09

Prospect

                                17
B. PACKAGE LEAFLET
18
PACKAGE LEAFLET: INFORMATION FOR THE USER
CHOLESTAGEL 625 MG FILM-COATED TABLETS
Colesevelam
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Cholestagel is and what it is used for
2.
What you need to know before you take Cholestagel
3.
How to take Cholestagel
4.
Possible side effects
5.
How to store Cholestagel
6.
Contents of the pack and other information
1.
WHAT CHOLESTAGEL IS AND WHAT IT IS USED FOR
Cholestagel contains the active substance colesevelam (as
hydrochloride). Taking Cholestagel helps to
lower the level of cholesterol in your blood. Your doctor should only
give you Cholestagel if a diet
low in fat and cholesterol did not work well enough on its own.
Cholestagel works in your intestinal system by binding bile acids
produced by your liver and carrying
the bile acids out of your body with your faeces. This prevents your
body from recycling the bile acids
from your intestines in the usual way. Without the recycling process,
your liver has to make additional
bile acids. Your liver uses cholesterol from your blood to do this,
which lowers the level of cholesterol
in your blood.
Cholestagel is prescribed to treat a condition known as primary
hypercholesterolaemia (when
cholesterol in the blood is elevated) in adults.
-
Cholestagel may be prescribed on its own in addition to a diet low in
fat and cholesterol when
treatment with a statin (a class of cholesterol-lowering medicines
that work in the liver) is
inappropriate or not well tolerated.
-
Cholestagel may be u
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Cholestagel 625 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 625 mg colesevelam (as hydrochloride).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Off-white, capsule-shaped film-coated tablets imprinted with
“C625” on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Cholestagel co-administered with a
3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase
inhibitor (statin) is indicated as adjunctive therapy to diet to
provide an additive reduction in
low-density lipoprotein cholesterol (LDL-C) levels in adult patients
with primary
hypercholesterolaemia who are not adequately controlled with a statin
alone.
Cholestagel as monotherapy is indicated as adjunctive therapy to diet
for reduction of elevated
total-cholesterol and LDL-C in adult patients with primary
hypercholesterolaemia, in whom a statin is
considered inappropriate or is not well-tolerated.
Cholestagel can also be used in combination with ezetimibe, with or
without a statin, in adult patients
with primary hypercholesterolaemia, including patients with familial
hypercholesterolaemia (see
section 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Combination therapy _
The recommended dose of Cholestagel for combination with a statin with
or without ezetimibe is 4 to
6 tablets per day. The maximum recommended dose is 6 tablets per day
taken as 3 tablets twice per
day with meals or 6 tablets taken once per day with a meal. Clinical
trials have shown that Cholestagel
and statins can be co-administered or dosed apart, and that
Cholestagel and ezetimibe can be co-
administered or dosed apart.
_ _
_Monotherapy _
The recommended starting dose of Cholestagel is 6 tablets per day
taken as 3 tablets twice per day
with meals or 6 tablets once per day with a meal. The maximum
recommended dose is 7 tablets per
day.
During therapy, the cholesterol-lowering diet shoul
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului bulgară 25-05-2021
Raport public de evaluare Raport public de evaluare bulgară 17-05-2010
Prospect Prospect spaniolă 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului spaniolă 25-05-2021
Raport public de evaluare Raport public de evaluare spaniolă 17-05-2010
Prospect Prospect cehă 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului cehă 25-05-2021
Raport public de evaluare Raport public de evaluare cehă 17-05-2010
Prospect Prospect daneză 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului daneză 25-05-2021
Raport public de evaluare Raport public de evaluare daneză 17-05-2010
Prospect Prospect germană 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului germană 25-05-2021
Raport public de evaluare Raport public de evaluare germană 17-05-2010
Prospect Prospect estoniană 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului estoniană 25-05-2021
Raport public de evaluare Raport public de evaluare estoniană 17-05-2010
Prospect Prospect greacă 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului greacă 25-05-2021
Raport public de evaluare Raport public de evaluare greacă 17-05-2010
Prospect Prospect franceză 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului franceză 25-05-2021
Raport public de evaluare Raport public de evaluare franceză 17-05-2010
Prospect Prospect italiană 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului italiană 25-05-2021
Raport public de evaluare Raport public de evaluare italiană 17-05-2010
Prospect Prospect letonă 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului letonă 25-05-2021
Raport public de evaluare Raport public de evaluare letonă 17-05-2010
Prospect Prospect lituaniană 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului lituaniană 25-05-2021
Raport public de evaluare Raport public de evaluare lituaniană 17-05-2010
Prospect Prospect maghiară 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului maghiară 25-05-2021
Raport public de evaluare Raport public de evaluare maghiară 17-05-2010
Prospect Prospect malteză 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului malteză 25-05-2021
Raport public de evaluare Raport public de evaluare malteză 17-05-2010
Prospect Prospect olandeză 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului olandeză 25-05-2021
Raport public de evaluare Raport public de evaluare olandeză 17-05-2010
Prospect Prospect poloneză 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului poloneză 25-05-2021
Raport public de evaluare Raport public de evaluare poloneză 17-05-2010
Prospect Prospect portugheză 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului portugheză 25-05-2021
Raport public de evaluare Raport public de evaluare portugheză 17-05-2010
Prospect Prospect română 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului română 25-05-2021
Raport public de evaluare Raport public de evaluare română 17-05-2010
Prospect Prospect slovacă 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului slovacă 25-05-2021
Raport public de evaluare Raport public de evaluare slovacă 17-05-2010
Prospect Prospect slovenă 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului slovenă 25-05-2021
Raport public de evaluare Raport public de evaluare slovenă 17-05-2010
Prospect Prospect finlandeză 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului finlandeză 25-05-2021
Raport public de evaluare Raport public de evaluare finlandeză 17-05-2010
Prospect Prospect suedeză 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului suedeză 25-05-2021
Raport public de evaluare Raport public de evaluare suedeză 17-05-2010
Prospect Prospect norvegiană 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului norvegiană 25-05-2021
Prospect Prospect islandeză 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului islandeză 25-05-2021
Prospect Prospect croată 25-05-2021
Caracteristicilor produsului Caracteristicilor produsului croată 25-05-2021

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor